Drugs giant reveals anti-flu spray sales boost

GlaxoSmithKline revealed sales of a key treatment against a potential flu pandemic have rocketed since January – on the day a new outbreak of bird flu was confirmed in the UK.

The pharmaceuticals giant said sales of its anti-viral Relenza drug totalled £7m (€10m) in the first three months of this year – compared with £5m (€7.2m) for the whole of 2005.